Serotonin, Norepinephrine and Dopamine Involvement in the Antidepressant Action of Hypericum Perforatum

Hypericum perforatum is considered an effective alternative to the synthetic antidepressants in the treatment of mild-to-moderate depression. Recently, we showed that the effects on neurotransmitter contents in different brain regions of laboratory animals are more evident after administration of hypericum extracts containing a higher concentration of flavonoids, thus suggesting that these compounds are important in the antidepressant action of hypericum perforatum. We studied the effects of Ph-50, a hypericum extract standardized to flavonoids (50 %) and containing 0.3 % hypericin and 4.5 % hyperforin on brain serotonin content, norepinephrine and dopamine by a high-performance liquid chromatography method in discrete brain areas (cortex, diencephalon and brainstem) in male Sprague-Dawley rats. Moreover, we evaluated the effects of Ph-50 alone or in association with sulpiride (a dopamine receptor antagonist), metergoline (a serotonin receptor antagonist) and 6-hydroxydopamine (6-OH-DA, destroying norepinephrine-containing neurons) using a forced-swimming test in the rat. Hypericum extract (Ph-50; 250 - 500 mg/kg) with acute oral administration enhanced serotonin, norepinephrine and dopamine content in the brain and reduced the immobility time of rats in the forced-swimming test. Sulpiride, metergoline and 6-OH-DA significantly increased the period of immobility in the forced-swimming test for the rats receiving hypericum extract (Ph-50). The results indicate that the neurotransmitters studied could be involved in the anti-immobility effects of hypericum, and suggest that its antidepressant action is probably mediated by serotonergic, noradrenergic and dopaminergic system activation.

References

• 1 Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of hypericum extract.  J Geriatric Psychiatr Neurol. 1994;  7 57-59
• 2 Bennett D A, Phun L, Polk J F, Voglino S A, Zlotnik V, Raffa R B. Neuropharmacology of St-John's Wort (Hypericum).  Ann Pharmacother. 1998;  32 1201-1208
• 3 Butterweck V, Wall A, Lieflander-Wulf L, Winterhoff H, Nahrstedt A. Effects of the total extract and fractions of hypericum perforatum in animal assays for antidepressant activity.  Pharmacopsychiatry. 1997;  30 (Suppl. 2) 117-124
• 4 Calapai G, Crupi A, Firenzuoli F, Inferrera G, Campo G M, Caputi A P. Effects of hypericum perforatum on levels of 5-Hydroxytryptamine. Noradrenaline and Dopamine in the cortex, diencephalon and brainstem of the rat.  J Pharm Pharmacol. 1999;  51 723-728
• 5 Calapai G, Corica F, Corsonello A, Sautebin L, Di Rosa M, Campo G M, Buemi M, Nicita Mauro V, Caputi A P. Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis.  J Clin Invest. 1999;  104 975-982
• 6 Cervo L, Grignaschi G, Rossi C, Samanin R. Role of central serotonergic neurons in the effect of sertraline in rats in the forced swimming test.  Eur J Pharmacol. 1991;  196 217-222
• 7 Cott J M. In vitro receptor binding and enzyme inhibition by hypericum perforatum extract.  Pharmacopsychiatry. 1997;  30 (Suppl. 2) 108-112
• 8 Delgado P, Moreno F. Antidepressants and the brain.  Int din Psychopharmacol. 1999;  1 (Suppl. 14) 9-16
• 9 De Saint Blanquat G, Lambouef Y, Fritsch P. Determination of catecholamines in biological tissues by liquid chromatography with coulometric detection.  fehlt. 1987;  415 388-392
• 10 Gobbi M, Dallavalle F, Ciapparelli C, Diomede L, Morazzoni P, Verotta L, Caccia S, Cervo L, Mennini T. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex.  Naunyn-Shmiedeberg's Archives of Pharmacology. 1999;  360 262-269
• 11 Grimaldi B, Bonnin A, Fillion M P, Prudhomme N, Fillion G. 5-Hydroxytriptamine-moduline: a novel endogenous peptide involved in the control of anxiety.  Neuroscience. 1999;  93 1223-1225
• 12 Hantraye P. Modeling dopamine system dysfunction in experimental animals.  Nucl Med Biol. 1998;  25 721-728
• 13 Hank S L. Locus coeruleus lesion by local 6-hydroxydopamine infusion causes marked and specific destruction of noradrenergic neurons, long-term depletion of norepinephrine and the enzymes that synthesize it, and enhanced dopaminergic mechanisms in the ipsilateral cerebral cortex.  J Neurosci. 1984;  4 699-707
• 14 Harrer G, Schulz V. Clinical investigation of the antidepressant effectiveness of hypericum.  J Geriatr Psychiatry Neurol. 1994;  7 (Suppl. 1) 6-8
• 15 Heinz A, Schmidt L G, Reischies F M. Anhedonia in schizophrenic, depressed, or alcohol-dependent patients-neurobiological correlates.  Pharmacopsychiatry. 1994;  27 (Suppl. 1) 7-10
• 16 Josey E S, Tackett R L. St John's wort: a new alternative for depression?.  Int J Clin Pharmacol Ther. 1999;  37 111-119
• 17 Kasper S. From symptoms to social functioning: differential effects of antidepressant therapy.  Int Clin Psychopharmacol. 1999;  14 27-31
• 18 Leonard B E. Mechanisms of action of antidepressants.  CNS Drugs. 1995;  4 (Suppl. 1) 1-12
• 19 Linde K, Ramirez G, Mulrow C D, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression - an overview and meta-analysis of randomized clinical trials.  Brit Med J. 1996;  313 253-258
• 20 Lookmann G, Schille C, Baghal T, Kleser M. St. John's Wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy.  Pharmacopsychiatry. 1998;  31 54-59
• 21 Lucki I. The forced-swimming test as a model for core and component behavioral effects of antidepressant drugs.  Behav Pharmacol. 1997;  8 523-532
• 22 Montgomery S A. Predicting response: norepinephrine reuptake inhibition.  Int Clin Psychopharmacol. 1999;  I (Suppl. 14) 21-26
• 23 Muller W E, Kasper S. Clinically used antidepressant drugs.  Pharmacopsychiatry. 1997;  2 (Suppl. 30) 71
• 24 Muller W E, Rolli M, Schafer C, Hafner U. Effects of hypericum extract (Li 160) in biochemical models of antidepressant activity.  Pharmacopsychiatry. 1997;  30 (Suppl. 2) 102-107
• 25 Muller W E, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract.  Pharmacopsychiatry. 1998;  31 (Suppl. 1) 16-21
• 26 Nathan P. The experimental and clinical pharmacology of St. John's Wort (Hypericum perforatum L.)  Mol. Psychiatry. 1999;  4 333
• 27 Paxinos F, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press London 1986
• 28 Porsolt R D, Anton G, Blavet N, Jafre M. Behavioral despair in rats: A new model sensitive to antidepressant.  Eur J Pharmacol. 1978;  47 379-391
• 29 Squadrito F, Calapai G, Altavilla D, Cucinotta D, Zingarelli B, Arcoraci V, Campo G M, Capuli A P. Central serotonergic system involvement in the anorexia induced by N^G nitro-L-arginine, an inhibitor of nitric oxide synthase.  Eur J Pharmacol. 1994;  255 51
• 30 Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H. Inhibition of monoamine oxidase by hypericin.  Planta Med. 1984;  50 272-274
• 31 Vitiello B. Hypericum perforatum extracts as potential antidepressants.  J Pharm Pharmacol. 1999;  51 513-517
• 32 Volz H P. Controlled clinical trials of hypericum extracts in depressed patients - an overview.  Pharmacopsychiatry. 1997;  2 (Suppl. 2) 72-76
• 33 Wheatley D. Li 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial.  Pharmacopsychiatry. 1997;  2 (Suppl. 30) 77
• 34 Wheatley D. Hypericum extract-Potential in the treatment of depression.  CNS Drugs. 1998;  9 431-440
• 35 Wheatly P. Hypericum in seasonal affective disorder (SAD).  Curr Med Opin. 1999 a;  15 33-37
• 36 Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action.  Int Clin Psychopharmacol. 1997;  3 (Suppl. 12) 7-14
• 37 Zuardi A W. 5-HT related drugs and human experimental anxiety.  Neurosci Biobehav Rev. 1990;  14 507-510